Research Analysts Offer Predictions for Amedisys Q1 Earnings

Amedisys, Inc. (NASDAQ:AMED) – Stock analysts at William Blair decreased their Q1 2025 earnings per share estimates for Amedisys in a report released on Thursday, February 27th. William Blair analyst M. Larew now forecasts that the health services provider will post earnings per share of $0.98 for the quarter, down from their previous forecast of $1.01. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.05 EPS, Q4 2025 earnings at $1.08 EPS and FY2025 earnings at $4.45 EPS.

Separately, Stephens reissued an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a research note on Wednesday, February 12th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Amedisys presently has an average rating of “Hold” and a consensus price target of $100.75.

Amedisys Stock Performance

Shares of AMED stock opened at $92.00 on Friday. The business’s 50-day moving average price is $91.41 and its 200-day moving average price is $93.21. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.51, a PEG ratio of 1.78 and a beta of 0.73. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%.

Hedge Funds Weigh In On Amedisys

Hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. raised its position in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after acquiring an additional 124 shares during the last quarter. HBW Advisory Services LLC bought a new stake in Amedisys in the fourth quarter worth approximately $38,000. Versant Capital Management Inc increased its holdings in Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in Amedisys in the fourth quarter worth approximately $55,000. Finally, KBC Group NV bought a new stake in Amedisys in the third quarter worth approximately $63,000. 94.36% of the stock is currently owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.